证券日报网讯 9月18日晚间，一心堂发布公告称，2025年中期权益分派方案为向全体股东每10股派发现 金红利2.00元（含税）。股权登记日为2025年9月24日，除权除息日为2025年9月25日。 （编辑 姚尧） ...

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-084 号 特别提示： 根据《公司法》《上市公司股份回购规则》等相关规定，一心堂药业集团股份有限公司（以 下简称"公司"或"本公司"）通过股份回购专用证券账户持有的本公司股份11,475,900股不 享有参与权益分派的权利。本次权益分派以2025年半年度权益分派方案实施时股权登记日的总 股本扣除公司回购专用账户股份数为基数，向全体股东每10股派发现金红利2元(含税)，不送红 股，不以资本公积金转增股本，本次现金分红总额为114,825,645.00（含税)。 公司2025年中期权益分派方案已获2025年9月16日召开的2025年度第二次临时股东会审议 通过，现将权益分派事宜公告如下： 一、股东会审议通过的权益分派方案情况 1、公司 2025 年度第二次临时股东会审议通过的利润分配方案为：公司决定以 2025 年半年 度权益分派方案实施时股权登记日的总股本扣除公司回购专用账户股份数为基数，向全体股东 每 10 股派发现金红利 2 元(含税)，不送红股，不以资本公积金转增股本，本次现金分红总额为 114,825,645.00（含税) ...

Core Insights - Royal jelly is a rare natural complex nutrient with significant value in enhancing immunity, anti-aging, endocrine regulation, and improving sleep [1][6] - China is the world's largest producer and exporter of royal jelly, with an annual production of nearly 1,000 tons, over 90% of which is for export [1][6] - In 2024, China's royal jelly exports reached 623.81 tons, an increase of 11.12 tons from 2023, with export value at 14.53 million USD, up by 1.89 million USD [1][6] - However, in the first seven months of 2025, exports declined by 16.5% in quantity and 20.2% in value due to natural factors affecting production and rising market prices [1][6] Industry Overview - Royal jelly, also known as bee milk, is secreted by young worker bees and is rich in active ingredients with various health benefits [3][4] - The industry has evolved through four stages: initial awareness, primary development, significant production increase, and modernized development with advanced technology [4][5] Industry Chain - The royal jelly industry chain includes upstream beekeeping and processing equipment, midstream manufacturers, and downstream sales channels such as health product companies and e-commerce platforms [5][6] Current Market Status - The market for royal jelly is competitive with numerous brands, where well-known brands dominate due to product quality and market share [6][10] - Key companies in the industry include Nanjing Laoshanyao Pharmaceutical Co., Ltd., Jiangxi Wang's Beekeeping Garden Co., Ltd., and Hangzhou Bee's Language Co., Ltd. [6][9] Export Data - Major export regions for Chinese royal jelly include Spain and Japan, accounting for over 50% of total exports [6][10] - In the first half of 2025, Zhejiang province led in exports, followed by Jiangsu and Shanghai, with varying growth rates across provinces [8][10] Future Trends - Market demand for royal jelly is expected to grow due to increasing consumer awareness of natural health products [10][11] - The industry is moving towards intelligent, automated, and sustainable production methods, enhancing efficiency and quality [11][12] - There is a trend towards functional and diversified products, with advancements in biotechnology enabling the development of customized health products [12]

中国北京市朝阳区建国路 77 号华贸中心 3 号写字楼 34 层 邮政编码 100025 电话: (86-10) 5809-1000 传真: (86-10) 5809-1100 北京市竞天公诚律师事务所 关于一心堂药业集团股份有限公司 致：一心堂药业集团股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）以及中国证券监 督管理委员会颁布的《上市公司股东会规则（2025年修订）》（以下简称"《股 东会规则》"）的规定，北京市竞天公诚律师事务所（以下简称"本所"）指派律 师对一心堂药业集团股份有限公司（以下简称"公司"）2025年度第二次临时股东 会（以下简称"本次股东会"）进行现场见证，并就本次股东会的有关事宜出具本 法律意见书。 本所及经办律师依据《中华人民共和国证券法》《律师事务所从事证券法律 业务管理办法（2023）》和《律师事务所证券法律业务执业规则（试行）》等规 定及本法律意见书出具日以前已经发生或者存在的事实，严格履行了法定职责， 遵循了勤勉尽责和诚实信用原则，进行了充分的核查验证，保证本法律意见书所 认定的事实真实、准确、完整，所发表的结论性意见合法、准确，不存在虚假记 载、误导性 ...

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-083 号 一心堂药业集团股份有限公司 2025 年度第二次临时股东会暨中小投资者表决结果公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1.本次股东会没有增加、否决或变更提案。 2.本次股东会不涉及变更前次股东会决议。 一、会议召开和出席情况 （一）会议召开情况 1.召开时间： （1）现场会议时间：2025 年 9 月 16 日（星期二）下午 14 点。 （2）网络投票时间：2025 年 9 月 16 日。其中，通过深圳证券交易所交易系统进行网络 投票的具体时间为 2025 年 9 月 16 日 9:15—9:25，9:30—11:30 和 13:00—15:00；通过深圳证 券交易所互联网投票系统进行网络投票的具体时间为 2025 年 9 月 16 日上午 9:15 至下午 15:00 的任意时间。 2.召开地点：一心堂药业集团股份有限公司会议室 股，占公司有表决权股份总数 574,128,225 股（注:截至本次股东会股权登记日，公司总股本 为 585,6 ...

Summary of Conference Call on Pharmacy Industry Industry Overview - The pharmacy industry is undergoing a transformation towards differentiation due to long-term profit erosion from drug sales. Future directions include professional monetization (embracing medical insurance and commercial insurance) and diversified transformation, characterized by the "thousand stores, thousand faces" approach and digital product selection [1][2]. Key Points and Arguments - **Challenges Facing the Pharmacy Industry**: The industry is experiencing slow growth due to economic changes, policy adjustments, and shifts in consumer habits post-pandemic. The trend of medical insurance cost control is impacting profitability [2][5]. - **Head Pharmacy Initiatives**: Leading pharmacies like YaoXingTang and YiFeng have cleared unprofitable stores and are piloting store upgrades. These upgrades are expected to significantly impact performance and valuation in 2025 and 2026 [3][4]. - **Market Valuation**: Current pharmacy valuations are at historical lows, indicating potential for upward movement as the industry undergoes transformation [4]. - **Membership System Issues**: The aging membership system is a concern, with 2024 data showing that average member consumption in the pharmacy industry is 69%. There is a need for younger consumer engagement [5]. - **Japanese Experience**: Japan's separation of medicine and pharmacy has led to significant increases in prescription outflow, providing a model for China to enhance its pharmacy ecosystem [6][7]. Additional Important Insights - **Diverse Product Strategies**: Pharmacies are diversifying their product offerings beyond medical insurance products to include items like beauty products and medical devices, which can enhance revenue and attract new customers [3][11]. - **Store Layout Strategies**: Pharmacies are adjusting their layouts based on customer demographics, such as introducing blind box products in areas with a high concentration of students [12]. - **Digital Transformation**: Leading pharmacies are advancing digital initiatives to monitor sales data, which will enhance operational efficiency and profitability [14]. - **Investment Opportunities**: Investors are encouraged to focus on companies like YaoXingTang and YiFeng, which are actively pursuing store renovations and innovative strategies to improve performance and valuation [15]. Conclusion The pharmacy industry is at a pivotal point, with significant challenges and opportunities for transformation. The focus on differentiation, digitalization, and adapting to consumer needs will be crucial for future growth and profitability.

Core Viewpoint - The article discusses the sudden decline of the pharmacy industry in China, highlighting the rapid closure of stores and the challenges faced by pharmacy owners and employees due to various market and regulatory changes [7][13][31]. Group 1: Industry Overview - In the past year, approximately 39,000 pharmacies closed nationwide, with a closure rate of 5.7%, and predictions suggest an additional 60,000 to 100,000 closures this year [13]. - The pharmacy industry, once considered a "golden track" for investment, has seen major players like Guoda Pharmacy and Shandong's Shuyupingmin Pharmacy struggling, with significant store closures and stock sell-offs by shareholders [16][31]. Group 2: Factors Contributing to Decline - The decline is attributed to three main factors: competition from community hospitals, the rise of online pharmacies, and tightening regulations on medical insurance reimbursements [34][41][49]. - Community hospitals have become popular among younger consumers, leading to a loss of clientele for pharmacies, particularly in the chronic disease segment [36][40]. - Online platforms have disrupted traditional pharmacy sales, offering lower prices and convenience, which has eroded the competitive edge of brick-and-mortar pharmacies [42][46]. Group 3: Financial Impact - Many listed pharmacy chains are experiencing significant profit declines, with net profit reductions starting at 60%, and some companies like Shuyupingmin facing potential losses of up to 220 million yuan [31][50]. - The shift in the market has forced many pharmacy owners to seek alternative employment, with some transitioning to factory work or food delivery services [22][23]. Group 4: Adaptation Strategies - Pharmacies are attempting to adapt by diversifying their offerings, such as incorporating health seminars and free health check-ups to build community ties and enhance customer loyalty [58][67]. - The future of the pharmacy industry is expected to focus on professional services and operational efficiency rather than mere expansion, with some pharmacies exploring AI-assisted consultations to improve service delivery [70].

Core Points - The Yunnan Provincial Drug Administration conducted quality supervision and spot checks on 294 batches of medical devices, with all inspection results meeting regulations [1][2][3] Group 1: Inspection Results - All 294 batches of medical devices inspected were found to comply with the relevant standards [1] - Specific products inspected included disposable nasal oxygen tubes, infusion sets, sterile syringes, and surgical gloves, all of which passed the quality checks [1][2][3] Group 2: Product Details - Notable products included: - Disposable nasal oxygen tubes from Henan Tuo Ren Best Medical Devices Co., Ltd. and Jiangxi Jingkangyu Medical Technology Co., Ltd. [1] - Disposable infusion sets from Shandong Weigao Group Medical Polymer Co., Ltd. and Jiangxi Hongda Medical Devices Group Co., Ltd. [1][2] - Sterile syringes from Yunnan Haodi Medical Devices Co., Ltd. [1] - Surgical gloves from Shanghai Kebo Medical Latex Products Co., Ltd. [1][2][3] Group 3: Regulatory Compliance - The inspections were conducted in accordance with the "Medical Device Supervision and Administration Regulations" and the "2025 Yunnan Province Medical Device Supervision and Spot Check Work Plan" [1] - The results indicate a strong compliance rate among medical device manufacturers in Yunnan Province [1][2]

Core Viewpoint - YXTT's stock price has shown fluctuations in recent trading sessions, with a year-to-date increase of 16.53% but a recent decline of 1.00% over the last five trading days [2] Group 1: Stock Performance - As of September 11, YXTT's stock price was 14.83 CNY per share, with a market capitalization of 8.685 billion CNY [1] - The stock has experienced a 2.05% decline during the trading session on September 11, with a trading volume of 41.0343 million CNY and a turnover rate of 0.69% [1] - Year-to-date, YXTT has appeared on the "Dragon and Tiger List" twice, with the most recent appearance on May 23, where it recorded a net buy of -4.0951 million CNY [2] Group 2: Financial Performance - For the first half of 2025, YXTT reported a revenue of 8.914 billion CNY, a year-on-year decrease of 4.20%, and a net profit attributable to shareholders of 250 million CNY, down 11.44% year-on-year [2] - Cumulative cash dividends since YXTT's A-share listing amount to 1.908 billion CNY, with 649 million CNY distributed over the past three years [3] Group 3: Shareholder Structure - As of June 30, 2025, YXTT had 33,900 shareholders, a decrease of 5.42% from the previous period, with an average of 11,712 circulating shares per shareholder, an increase of 5.73% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 18.5744 million shares, a decrease of 21.1993 million shares from the previous period [3] - New entrants among the top ten shareholders include several funds, such as Guangfa Technology Innovation Mixed Fund and Invesco Great Wall Growth Star Stock A [3]

Core Insights - The traditional pharmacy industry in China is facing significant transformation challenges due to changing economic conditions, industry policies, and consumer habits, necessitating a differentiated approach to development [1][3][9] Group 1: Industry Transformation - The pharmacy industry must break through homogenized development and pursue differentiated transformation to address various pain points, including slowing growth, high store counts, and the need to attract younger consumers [1][3] - The Chinese pharmacy market is likely to split into two categories: specialized pharmacies focusing on professional medication needs and diversified pharmacies catering to daily health requirements [1][3] Group 2: Specialized Pharmacy Development - Specialized pharmacies are expected to respond to policy directions by actively engaging in prescription outflow, with a focus on enhancing professional capabilities [4][5] - The dual-channel policy is anticipated to accelerate the outflow of prescriptions to retail pharmacies, improving drug accessibility [5][6] Group 3: Diversified Pharmacy Development - Diversified pharmacies are encouraged to adopt a health care philosophy, utilizing digitalization to tailor product offerings and store layouts to specific consumer demographics [7][8] - The transformation costs for diversified pharmacies are relatively low, allowing for a shift in focus from traditional drug sales to a variety of health-related products [7] Group 4: Market Outlook - The industry is expected to experience a mild recovery by 2025, driven by ongoing trends in prescription outflow and increased market concentration [9] - Key players in the pharmacy sector, such as Yifeng Pharmacy, Yixin Hall, and Dazhenlin, are highlighted for their strong operational resilience and diverse transformation strategies [9]